Traditional therapies target neurohormonal pathways, newer pharmacological agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, soluble guanylate cyclase (sGC) stimulators, and cardiac myosin activators offer multi-targeted interventions with significant benefits in both HF with reduced ejection fraction (HFrEF ≤40%) and HFpEF [4]. This evidence concerns the gene SGCB and hydrops fetalis.